Newcells Biotech testing an in-vitro model of the human lung epithelium for application in the fight against SARS-CoV-2

Internationally renowned company, Newcells Biotech, are using their established expertise in human induced pluripotent stem cell (hiPSC) technology to test their existing model of the human lung epithelium as a platform for modelling SARS-CoV-2 infection and anti-viral strategies.

Newcells Biotech have been developing the lung model for over two years and have recently confirmed the model expresses the mRNA for key surface receptor, ACE2, that the SAR-CoV-2 virus uses to access cell. They are currently testing for the presence of the ACE2 protein on the cell surface. The model has been characterised and contains basal epithelia, ciliated and secretory cells (goblet and club cells) organised in a stratified epithelium. 

Once expression of ACE2 protein has been confirmed, the model will be challenged with the virus to confirm infection and replication.  Newcells is currently working with two BL3 registered laboratories to establish the protocols for the challenge experiments. 

Prior to the Covid-19 pandemic, Newcells Biotech had been developing a hiPSC (stem cell) derived model of the upper airway for toxicology testing of environmental pollutants and had developed a proprietary method to make the basal cells in large quantities. The model, which model is produced in 24-well TranswellTM insert format making it easy to scale up production and use, has been shown to respond to known airborne particles with cytokine responses and changes in gene expression.   

Newcells is rapidly working to demonstrate the utility of the assay to help researchers in the race to find anti-viral approaches to combat the pandemic in the short-term and to use as a platform to study the virus biology. 

 Newcells Biotech would be interested in collaborating with other organisations and companies. 

 For more information on the Newcells Biotech upper airways lung iPSC model, click here or contact us for a technical specification. 

You might also be interested in…

Development of functioning in vitro lung assay for modelling Covid-19 infection

Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform for modelling SARS-CoV-2 infection and replication.  Their work alongside the Liverpool School of Tropical Medicine (LTSM) Centre for Drugs and Diagnostics will be crucial in helping

The Biosphere

Newcells Biotech scales up its operations in The Biosphere

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.    The purpose-built space in the city centre site

COVID-19 Vaccine

An Overview of Vaccine Development & Sub-Types

Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have declined for a multitude of diseases, such as Diphtheria, Whooping Cough and Measles.1 However, despite the success of these global vaccination